552 related articles for article (PubMed ID: 26604731)
1. Erdosteine reduces inflammation and time to first exacerbation postdischarge in hospitalized patients with AECOPD.
Moretti M; Fagnani S
Int J Chron Obstruct Pulmon Dis; 2015; 10():2319-25. PubMed ID: 26604731
[TBL] [Abstract][Full Text] [Related]
2. Efficacy of erdosteine 900 versus 600 mg/day in reducing oxidative stress in patients with COPD exacerbations: Results of a double blind, placebo-controlled trial.
Dal Negro RW; Visconti M; Turco P
Pulm Pharmacol Ther; 2015 Aug; 33():47-51. PubMed ID: 26116425
[TBL] [Abstract][Full Text] [Related]
3. Effect of Erdosteine on COPD Exacerbations in COPD Patients with Moderate Airflow Limitation.
Calverley PM; Page C; Dal Negro RW; Fontana G; Cazzola M; Cicero AF; Pozzi E; Wedzicha JA
Int J Chron Obstruct Pulmon Dis; 2019; 14():2733-2744. PubMed ID: 31819405
[TBL] [Abstract][Full Text] [Related]
4. Effect of erdosteine on the rate and duration of COPD exacerbations: the RESTORE study.
Dal Negro RW; Wedzicha JA; Iversen M; Fontana G; Page C; Cicero AF; Pozzi E; Calverley PMA; ;
Eur Respir J; 2017 Oct; 50(4):. PubMed ID: 29025888
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety profile of mucolytic/antioxidant agents in chronic obstructive pulmonary disease: a comparative analysis across erdosteine, carbocysteine, and N-acetylcysteine.
Rogliani P; Matera MG; Page C; Puxeddu E; Cazzola M; Calzetta L
Respir Res; 2019 May; 20(1):104. PubMed ID: 31133026
[TBL] [Abstract][Full Text] [Related]
6. Optimization of Nebulized Budesonide in the Treatment of Acute Exacerbation of Chronic Obstructive Pulmonary Disease.
Zhang R; Zhu J; Liu Y; Li Y; Liu W; Zhang M; Chen B; Zhu S
Int J Chron Obstruct Pulmon Dis; 2020; 15():409-415. PubMed ID: 32161453
[TBL] [Abstract][Full Text] [Related]
7. Use of mucolytics in COPD: A Delphi consensus study.
Papi A; Avdeev S; Calverley PMA; Cordeiro CR; Jesenak M; Koblížek V; Petkova D; Rogliani P; Tarraf H; Tzanakis N; Ulmeanu R; Uzaslan E; Adir Y
Respir Med; 2020 Dec; 175():106190. PubMed ID: 33217537
[TBL] [Abstract][Full Text] [Related]
8. Erdosteine reduces the exercise-induced oxidative stress in patients with severe COPD: Results of a placebo-controlled trial.
Dal Negro RW; Visconti M
Pulm Pharmacol Ther; 2016 Dec; 41():48-51. PubMed ID: 27651323
[TBL] [Abstract][Full Text] [Related]
9. The therapeutic efficacy of erdosteine in the treatment of chronic obstructive bronchitis: a meta-analysis of individual patient data.
Cazzola M; Floriani I; Page CP
Pulm Pharmacol Ther; 2010 Apr; 23(2):135-44. PubMed ID: 19854285
[TBL] [Abstract][Full Text] [Related]
10. Erdosteine: its relevance in COPD treatment.
Moretti M
Expert Opin Drug Metab Toxicol; 2009 Mar; 5(3):333-43. PubMed ID: 19331595
[TBL] [Abstract][Full Text] [Related]
11. The effect of long-term treatment with erdosteine on chronic obstructive pulmonary disease: the EQUALIFE Study.
Moretti M; Bottrighi P; Dallari R; Da Porto R; Dolcetti A; Grandi P; Garuti G; Guffanti E; Roversi P; De Gugliemo M; Potena A;
Drugs Exp Clin Res; 2004; 30(4):143-52. PubMed ID: 15553660
[TBL] [Abstract][Full Text] [Related]
12. Serum levels of IGFBP7 are elevated during acute exacerbation in COPD patients.
Ruan W; Wu M; Shi L; Li F; Dong L; Qiu Y; Wu X; Ying K
Int J Chron Obstruct Pulmon Dis; 2017; 12():1775-1780. PubMed ID: 28684903
[TBL] [Abstract][Full Text] [Related]
13. Effect of sequential treatment with TCM syndrome differentiation on acute exacerbation of chronic obstructive pulmonary disease and AECOPD risk window.
Jiansheng L; Haifeng W; Suyun L; Hailong Z; Xueqing Y; Xiaoyun Z; Fengsen L; Xianmei Z; Zikai S; Yimin M; Lijun M; Yijie Z; Guojun Z; Bingxiang T
Complement Ther Med; 2016 Dec; 29():109-115. PubMed ID: 27912934
[TBL] [Abstract][Full Text] [Related]
14. Inflammatory changes, recovery and recurrence at COPD exacerbation.
Perera WR; Hurst JR; Wilkinson TM; Sapsford RJ; Müllerova H; Donaldson GC; Wedzicha JA
Eur Respir J; 2007 Mar; 29(3):527-34. PubMed ID: 17107990
[TBL] [Abstract][Full Text] [Related]
15. Effects of High-Dose Vitamin D Replacement on the Serum Levels of Systemic Inflammatory Biomarkers in Patients with Acute Exacerbation of Chronic Obstructive Pulmonary Disease.
Dastan F; Salamzadeh J; Pourrashid MH; Edalatifard M; Eslaminejad A
COPD; 2019 Aug; 16(3-4):278-283. PubMed ID: 31550915
[TBL] [Abstract][Full Text] [Related]
16. Inflammatory biomarkers and exacerbations in chronic obstructive pulmonary disease.
Thomsen M; Ingebrigtsen TS; Marott JL; Dahl M; Lange P; Vestbo J; Nordestgaard BG
JAMA; 2013 Jun; 309(22):2353-61. PubMed ID: 23757083
[TBL] [Abstract][Full Text] [Related]
17. Serum Endostatin Is a Novel Marker for COPD Associated with Lower Lung Function, Exacerbation and Systemic Inflammation.
Wu Y; Qin J; He J; Shen Y; Wang H; Li Y; Zeng Q; Dong J; An Y; Xiong S; Feng M; Wen F
Int J Chron Obstruct Pulmon Dis; 2020; 15():397-407. PubMed ID: 32158205
[TBL] [Abstract][Full Text] [Related]
18. Expiratory flow limitation relates to symptoms during COPD exacerbations requiring hospital admission.
Jetmalani K; Timmins S; Brown NJ; Diba C; Berend N; Salome CM; Wen FQ; Chen P; King GG; Farah CS
Int J Chron Obstruct Pulmon Dis; 2015; 10():939-45. PubMed ID: 25999709
[TBL] [Abstract][Full Text] [Related]
19. A randomized, controlled multicentric study of inhaled budesonide and intravenous methylprednisolone in the treatment on acute exacerbation of chronic obstructive pulmonary disease.
Ding Z; Li X; Lu Y; Rong G; Yang R; Zhang R; Wang G; Wei X; Ye Y; Qian Z; Liu H; Zhu D; Zhou R; Zhu K; Ni R; Xia K; Luo N; Pei C
Respir Med; 2016 Dec; 121():39-47. PubMed ID: 27888990
[TBL] [Abstract][Full Text] [Related]
20. Systemic Inflammatory Marker CRP Was Better Predictor of Readmission for AECOPD Than Sputum Inflammatory Markers.
Jing Z; Chun C; Ning S; Hong Z; Bei H; Wan-Zhen Y
Arch Bronconeumol; 2016 Mar; 52(3):138-44. PubMed ID: 26002550
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
